IRCT20200105046010N54招募中未知
in- Vivo Bioequivalence study of Finasteride tablet 5 mg Aburaihan Pharma (FINIDE® 5 mg FC.Tablets, Aburaihan, Iran) with brand drug (PROSCAR® 5 mg, FC. Tablets, MSD,Germany) in Iranian healthy volunteers.
Aburayhan Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index between18-28
- •Informed consent
- •Being at the age of 18-55 years old
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
招募中
Unknown
Comparative in vivo evaluation of 2 Finasteride 5 mg Tablet formulations.IRCT20180620040164N55Iran Hormone Pharmaceutical Co.24
已完成
1 期
Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mgHealthyNCT00648791Mylan Pharmaceuticals Inc29
已完成
3 期
Effect of finasterid on COVID-19 treatmentCorona virus pneumonia.COVID-19,virus not identifiedU07.2IRCT20200505047318N1Qazvin University of Medical Sciences80
已完成
1 期
Fed Study of Finasteride Tablets 5 mg and Proscar® Tablets 5 mgHealthyNCT00650377Mylan Pharmaceuticals Inc30
已完成
1 期
Finasteride 5 mg Tablets Under Fasting ConditionsHealthyNCT00835666Teva Pharmaceuticals USA32